URayos okanye iPrednisone - Okufuneka Ukwazi

I-Corticosteroid iFomelwe ukuKhutshwa koKhutshwa

URayos ( prednisone ), owaziwa ngokuba yiLodotra eYurophu, ukuqulunqwa kwexesha lokukhutshwa kwe-dose prednisone. URayos, owenziwe ngu-Horizon Pharma, wamukelwa yi-US Food and Drug Administration (FDA) ngoJulayi 26, 2012, ngesifo se-rheumatoid kunye nezinye izibonakaliso.

Imvume ye-FDA isekelwe kwidatha efanisa i-pharmacokinetics (oko kukuthi, ukuba isilwanyana sithatha njani, sagqitywa, sichithwa) sikaRayos ukuya kwi-prednisone yokukhululwa ngokukhawuleza, kunye nedatha evela kwi-Circadian Administration ye-Prednisone ku-RA (i-CAPRA-1 ne-2 ) uvavanyo.

I-CAPRA-2 ibonisa ukuba abantu abaneemodareyithithi ezinzulu zesifo se-rheumatoid abaye baphathwa noRayos bafumana ukuphucula okubalulekayo kwi- ACR20 imilinganiselo yeempendulo xa kuthelekiswa ne-placebo, kunye nokuphuculwa okukhulu kwinqanaba lokukhathala. I-CAPRA-1 ihlolwe ukhuseleko jikelele kaRayos.

Iinkcazo

U-Rayos uyi- corticosteroid eneempembelelo ezichasayo okanye izigulane ezingasetyenziswayo ekusebenziseni ukunyanga, i-dermatologic, i-endocrine, isisu, i-hematologic, i-neoplastic, inkqubo ye-nervous, i-ophthalmologic, i-renal, i-breathing, ne-rheumatologic.

Ngokubhekiselele kwiimeko ze-rheumatologic, uRayos angasetyenziselwa ukukhutshwa kwexesha elifutshane leqhekeza elincinci le-arthritis. I-Rayos ingasetyenziselwa kwezinye iimeko ze- spondylitis e-ankylosing , i-dermatomyositis, i-polymyositis, i- polymyalgia rheumatica , i- psoriatic arthritis , ibuyele i-polychondritis, i-rheumatoid arthritis, i- Sjogren's syndrome , i- systemic lupus erythematosus kunye ne- vasculitis .

Ukufumaneka

URayos ufumaneka njengo-1 mg., 2 mg, kunye no-5 mg. ithebhulethi yokukhululwa.

Ukukhetha

Ukuzikhethela kufuneka kube ngabanye ngokucatshungulwa okunikezelwa kwisifo esiqinileyo nokuba ngaba izigulane zisetyenziswa ngokusesikweni kwangoko-prednisone. Umthamo wokuqala usu-5 mg. kaRayos kanye ngosuku. Nangona kunjalo, izigulane ezidlulileyo kwi-prednisone zingadinga ukulungiswa kwenzuliso ukuze zenze okulinganayo xa zisuka kuRayos.

URayos kufuneka athathwe ngokutya, kwaye ithebhulethi kufuneka ifakwe ngokupheleleyo. Ukulondolozwa, i-dose esebenzayo kakhulu kufuneka isetyenziswe. Ukuyeka ukutshintshana kufuneka kufutshane.

Izimpembelelo ezimbi

Ukusetyenziswa kwezinto eziqhelekileyo ezichaphazelekayo kunye nokusetyenziswa kwe-corticosteroid kubandakanya ukugcinwa kwamanzi, ukuphakama kwegazi, ukutshintsha kwimeko yokunyamezela kwe-glucose, ukutshintsha kwemizwelo, ukufumana ubunzima, nokunyusa ukutya.

Kukhona ezinye iimpendulo ezimbi ezinokuthi zidibaniswe neninzi yeenkqubo zomzimba. Ulwazi olupheleleyo olupheleleyo lweRayos luqulethe uluhlu olubanzi. Izimpembelelo ezingalunganga zeMusculoskeletal ezihambisana ne-corticosteroids zibandakanya i- osteonecrosis yeentloko zowesifazane kunye nezobuhlungu, i- osteoporosis , ubuthathaka bomzimba, ukulahleka kobunzima bomzimba, ukuhlukana komzimba kunye nokuphuka kwetonon.

Ukungqinelana

URayos akufanele asetyenziswe zizigulane ezine-hypersensitivity eyaziwayo kwi-prednisone okanye ezinye izithako ezingasebenzi ezingezantsi kwithebhulethi.

Izilumkiso

Ukusebenzisana kweziyobisi

URayos unokusebenzisana naye:

Qiniseka ukuba ugqirha wakho uyazi zonke iyeza kunye nezibonelelo ezithathayo ngoku. Kubalulekile ukuvavanya umngcipheko onokumelana nokuxhamla okunokwenzeka kwonyango kunye noRayos.

Yintoni eyahlukileyo?

U-Rayos uhlukile njani kwi-prednisone ngokukhawuleza? Kwiimvavanyo zeclini, uRayos wayelawulwa nge-10 ntambama ngokutya. Ubume bokukhululwa kwe-Rayos obunokulibaziseka buvumelekile ukuba inqanaba lokuthathwa kwe-prednisone egazini lenzeke xa amazinga e- cytokine aqala ukwanda phakathi kobusuku. Le ndlela yesenzo inokubonelela ngakumbi ukulawula ukuvuvukala kwezinye izigulane.

Imithombo

Rayos. Ulwaziso loLwazi.
http://www.rayosrx.com/PI/RAYOS-Ukuchaza-Information.pdf

I-Horizon Pharma Izisa i-FDA Ukuvunyelwa kweRAYOS® (prednisone) Iibhulile ezikhutshiwe ezichithwe kwi-Rheumatoid Arthritis kunye neenkcukacha ezininzi ezongezelelweyo. Horizon Pharma. Julayi 2012.
http://ir.horizon-pharma.com/releasedetail.cfm?ReleaseID=695983